EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The glucose transporter GLUT12, a new actor in obesity and cancer

Miguel Burgos, Eva Gil-Iturbe, Adrián Idoate-Bayón, Rosa Castilla-Madrigal, Maria J Moreno-Aliaga, M Pilar Lostao

Journal of Physiology and Biochemistry · 2025-05 · 81 (2) · 391-401

DOI: 10.1007/s13105-024-01028-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Physiology and Biochemistry, online erschienen am 10.05.2024. Verfasst von Miguel Burgos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nutrition Research and Department of Nutrition, Food Science and Physiology; School of Pharmacy and Nutrition, University of Navarra, Pamp…. Hauptthemen laut MEDLINE: Obesity, Neoplasms, Glucose Transport Proteins, Facilitative. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MCIN/AEI/10.13039/501100011033, Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain, MCIN/AEI/10.13039/501100011033, Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity constitutes a global health epidemic which worsens the main leading death causes such as type 2 diabetes, cardiovascular diseases, and cancer. Changes in the metabolism in patients with obesity frequently lead to insulin resistance, along with hyperglycemia, dyslipidemia and low-grade inflammation, favoring a more aggressive tumor microenvironment. One of the hallmarks of cancer is the reprogramming of the energy metabolism, in which tumor cells change oxidative phosphorylation to aerobic glycolysis or “Warburg effect”. Aerobic glycolysis is faster than oxidative phosphorylation, but less efficient in terms of ATP production. To obtain sufficient ATP, tumor cells increase glucose uptake by the glucose transporters of the GLUT/SLC2 family. The human glucose transporter GLUT12 was isolated from the breast cancer cell line MCF7. It is expressed in adipose tissue, skeletal muscle and small intestine, where insulin promotes its translocation to the plasma membrane. Moreover, GLUT12 over‐expression in mice increases the whole‐body insulin sensitivity. Thus, GLUT12 has been proposed as a second insulin‐responsive glucose transporter. In obesity, GLUT12 is downregulated and does not respond to insulin. In contrast, GLUT12 is overexpressed in human solid tumors such as breast, prostate, gastric, liver and colon. High glucose concentration, insulin, and hypoxia upregulate GLUT12 both in adipocytes and tumor cells. Inhibition of GLUT12 mediated Warburg effect suppresses proliferation, migration, and invasion of cancer cells and xenografted tumors. This review summarizes the up-to-date information about GLUT12 physiological role and its implication in obesity and cancer, opening new perspectives to consider this transporter as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityNeoplasmsGlucose Transport Proteins, FacilitativeHumansAnimalsInsulin ResistanceGlucoseGlucose Transporter Type 2

Stichwörter der Autor:innen

CancerGLUT12ObesityWarburg effect

Substanzen

Glucose Transport Proteins, FacilitativeGlucoseSLC2A2 protein, humanGlucose Transporter Type 2

Autor:innen und Institutionen

  • Center for Nutrition Research and Department of Nutrition, Food Science and Physiology; School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
  • CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Center for Nutrition Research and Department of Nutrition, Food Science and Physiology; School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. plostao@unav.es.
  • IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. plostao@unav.es.

Förderung

  • MCIN/AEI/10.13039/501100011033
  • Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain, MCIN/AEI/10.13039/501100011033
  • Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición

Zitieren

APA

Burgos, M., Gil-Iturbe, E., Idoate-Bayón, A., Castilla-Madrigal, R., Moreno-Aliaga, M. J., & Lostao, M. P. (2025). The glucose transporter GLUT12, a new actor in obesity and cancer. Journal of Physiology and Biochemistry, 81(2), 391-401. https://doi.org/10.1007/s13105-024-01028-9

Vancouver

Burgos M, Gil-Iturbe E, Idoate-Bayón A, Castilla-Madrigal R, Moreno-Aliaga MJ, Lostao MP. The glucose transporter GLUT12, a new actor in obesity and cancer. Journal of Physiology and Biochemistry. 2025;81(2):391-401. doi:10.1007/s13105-024-01028-9

BibTeX
@article{Burgos2025,
  author = {Burgos, Miguel and Gil-Iturbe, Eva and Idoate-Bayón, Adrián and Castilla-Madrigal, Rosa and Moreno-Aliaga, Maria J and Lostao, M Pilar},
  title = {The glucose transporter GLUT12, a new actor in obesity and cancer},
  journal = {Journal of Physiology and Biochemistry},
  year = {2025},
  volume = {81},
  number = {2},
  pages = {391--401},
  doi = {10.1007/s13105-024-01028-9}
}
Kostenlos starten →